Disarm has discovered novel, potent SARM1 inhibitors and is advancing them into preclinical development for diseases including peripheral neuropathy as well as ALS and MS. Axonal degeneration is a ...

Advancium's funding will support two parallel preclinical studies focused on ASHA-624, a novel first-in-class molecular glue targeting SARM1 designed by Asha Therapeutics. SARM1 is a key driver of ...